Altimmune, Inc. (ALT)
4.30
-0.16
(-3.59%)
USD |
NASDAQ |
Feb 27, 16:00
4.30
0.00 (0.00%)
After-Hours: 06:26
Altimmune Research and Development Expense (TTM) : 67.72M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amgen, Inc. | 7.281B |
| Eli Lilly & Co. | 13.34B |
| Viking Therapeutics, Inc. | 344.96M |
| CorMedix, Inc. | 12.46M |
| Actinium Pharmaceuticals, Inc. | 20.82M |